Table 1.
Characteristics of t2t courses
| Ineffective | |||||
|---|---|---|---|---|---|
| Overall | No | Yes | P-Value | ||
| T2T courses (n) | 1843 | 1724 | 119 | ||
| BMI, mean (SD), (kg/m2) | 26.4 (4.8) | 26.5 (4.8) | 26.4 (4.4) | 0.830 | |
| Age, mean (SD), year | 56.1 (13.6) | 56.0 (13.6) | 58.5 (13.5) | 0.054 | |
| Gender, n (%) | M | 407 (22.1) | 380 (22.0) | 27 (22.7) | 0.960 |
| F | 1436 (77.9) | 1344 (78.0) | 92 (77.3) | ||
| Disease duration, mean (SD), year | 10.4 (8.7) | 10.4 (8.7) | 11.4 (9.6) | 0.257 | |
| IV administration, n (%) | No | 1610 (87.4) | 1507 (87.4) | 103 (86.6) | 0.897 |
| Yes | 233 (12.6) | 217 (12.6) | 16 (13.4) | ||
| MTX co-therapy, n (%) | No | 824 (44.7) | 766 (44.4) | 58 (48.7) | 0.413 |
| Yes | 1019 (55.3) | 958 (55.6) | 61 (51.3) | ||
| Other DMARD co-therapy, n (%) | No | 1545 (83.8) | 1454 (84.3) | 91 (76.5) | 0.033 |
| Yes | 298 (16.2) | 270 (15.7) | 28 (23.5) | ||
| GC co-therapy, n (%) | No | 1156 (62.7) | 1105 (64.1) | 51 (42.9) | < 0.001 |
| Yes | 687 (37.3) | 619 (35.9) | 68 (57.1) | ||
| Previous aTNF therapy, n (%) | No | 1233 (66.9) | 1168 (67.7) | 65 (54.6) | 0.004 |
| Yes | 610 (33.1) | 556 (32.3) | 54 (45.4) | ||
| HAQ, mean (SD) | 1.0 (0.7) | 1.0 (0.7) | 1.2 (0.7) | 0.015 | |
| Rheuma-factor-positivity, n (%) | No | 480 (30.0) | 443 (29.6) | 37 (35.6) | 0.241 |
| Yes | 1120 (70.0) | 1053 (70.4) | 67 (64.4) | ||
| VAS-Pat., mean (SD), mm | 39.6 (24.4) | 38.7 (24.2) | 51.1 (24.6) | < 0.001 | |
| VAS-Ph., mean (SD), mm | 28.7 (20.1) | 28.4 (20.1) | 32.4 (20.4) | 0.047 | |
| Anti-CCP, n (%) | No | 409 (33.2) | 380 (32.8) | 29 (39.2) | 0.317 |
| Yes | 823 (66.8) | 778 (67.2) | 45 (60.8) | ||
| TJC, mean (SD) | 4.5 (4.7) | 4.4 (4.6) | 6.0 (5.8) | 0.006 | |
| SJC, mean (SD) | 3.0 (2.9) | 2.9 (2.9) | 3.6 (2.8) | 0.020 | |
| CRP, mean (SD), mg/dL | 8.9 (15.4) | 8.6 (15.0) | 11.9 (19.8) | 0.102 | |
| ESR, mean (SD), mm/h | 19.1 (17.9) | 18.9 (17.7) | 22.5 (20.8) | 0.094 | |
| DAS28-ESR, mean (SD) | 3.8 (1.5) | 3.8 (1.5) | 4.1 (1.5) | 0.101 | |
| Smoker, n (%) | Current | 161 (8.7) | 151 (8.8) | 10 (8.4) | 0.978 |
| Past | 87 (4.7) | 81 (4.7) | 6 (5.0) | ||
| Never | 1595 (86.5) | 1492 (86.5) | 103 (86.6) | ||
aTNF anti-tumor necrosis factor, CRP C-reactive protein, DAS28 Disease Activity Score 28, ESR erythrocyte sedimentation rate, TJC tender joint count, HAQ Health Assessment Questionnaire, SJC swollen joint count, VAS-Pat. visual analogue scale patient, VAS-Ph. visual analogue scale physician, Anti-CCP anti-cyclic citrullinated peptide, MTX methotrexate, IV Administration, intravenous administration, GC glucocorticoid